drugset / Trial / NCT05945407
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
Recruiting
57 enrolled
Peking University People's Hospital
Beijing Chao Yang Hospital · collabGuang'anmen Hospital of China Academy of Chinese Medical Sciences · collabPeking Union Medical College Hospital · collabPeking University Third Hospital · collabQilu Hospital of Shandong University · collabShengjing Hospital · collabThird Military Medical University · collabTianjin Medical University General Hospital · collabTongji Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1/2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.
Timeline
- Start
- 2016-08-01
- Primary completion
- 2023-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dydrogesterone | Other / unclassified | — | — |
| Subject | Goserelin | Other / unclassified | 3.75 mg | Subcutaneous |
| Subject | Leuprolide | Other / unclassified | 3.75 mg | Subcutaneous |
| Subject | Levonorgestrel | Small molecule | — | — |
| Subject | Megestrol Acetate | Other / unclassified | 160 mg | Oral |
| Subject | Megestrol Acetate | Other / unclassified | 320 mg | Oral |
| Subject | Progesterone | Other / unclassified | — | — |
| Subject | Triptorelin | Other / unclassified | 3.75 mg | Subcutaneous |
| Subject | medroxyprogesterone acetate | Other / unclassified | 250 mg | Oral |
| Subject | medroxyprogesterone acetate | Other / unclassified | 500 mg | Oral |